BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations
- PMID: 31038410
- DOI: 10.1148/radiol.2019181814
BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations
Abstract
Patients who carry the BRCA1 and BRCA2 gene mutations have an underlying genetic predisposition for breast and ovarian cancers. These deleterious genetic mutations are the most common genes implicated in hereditary breast and ovarian cancers. This monograph summarizes the evidence behind current screening recommendations, reviews imaging protocols specific to this patient population, and illustrates some of the imaging nuances of breast and ovarian cancers in this clinical setting.
© RSNA, 2019.
Comment in
-
Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.Radiology. 2019 Nov;293(2):480-481. doi: 10.1148/radiol.2019191306. Epub 2019 Sep 3. Radiology. 2019. PMID: 31478804 No abstract available.
Similar articles
-
Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.Breast Cancer Res Treat. 2018 Jul;170(1):189-196. doi: 10.1007/s10549-018-4726-x. Epub 2018 Feb 22. Breast Cancer Res Treat. 2018. PMID: 29470806
-
High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.Breast Cancer Res Treat. 2018 Apr;168(3):695-702. doi: 10.1007/s10549-017-4635-4. Epub 2018 Jan 2. Breast Cancer Res Treat. 2018. PMID: 29297111
-
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.Breast Cancer Res Treat. 2010 Sep;123(2):581-5. doi: 10.1007/s10549-010-0818-y. Epub 2010 Mar 11. Breast Cancer Res Treat. 2010. PMID: 20221693
-
Prevention and Screening in Hereditary Breast and Ovarian Cancer.Oncology (Williston Park). 2016 Oct 15;30(10):896-904. Oncology (Williston Park). 2016. PMID: 27753056 Review.
-
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.Klin Onkol. 2019 Summer;32(Supplementum2):51-71. doi: 10.14735/amko2019S51. Klin Onkol. 2019. PMID: 31409081 Review. English.
Cited by
-
Modulation of Secondary Cancer Risks from Radiation Exposure by Sex, Age and Gonadal Hormone Status: Progress, Opportunities and Challenges.J Pers Med. 2022 Apr 30;12(5):725. doi: 10.3390/jpm12050725. J Pers Med. 2022. PMID: 35629147 Free PMC article. Review.
-
The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients With Germline Pathogenic Variants in Cancer Predisposition Genes.Front Oncol. 2021 Jul 13;11:710156. doi: 10.3389/fonc.2021.710156. eCollection 2021. Front Oncol. 2021. PMID: 34336698 Free PMC article.
-
Up-regulation of SPC25 promotes breast cancer.Aging (Albany NY). 2019 Aug 10;11(15):5689-5704. doi: 10.18632/aging.102153. Epub 2019 Aug 10. Aging (Albany NY). 2019. PMID: 31400751 Free PMC article.
-
Evaluating the utility of multi-gene, multi-disease population-based panel testing accounting for uncertainty in penetrance estimates.NPJ Genom Med. 2024 May 17;9(1):30. doi: 10.1038/s41525-024-00414-y. NPJ Genom Med. 2024. PMID: 38760335 Free PMC article.
-
Breast cancer risk characteristics of women undergoing whole-breast ultrasound screening versus mammography alone.Cancer. 2023 Aug 15;129(16):2456-2468. doi: 10.1002/cncr.34768. Epub 2023 Jun 12. Cancer. 2023. PMID: 37303202 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous